 The safety trial was conducted in over 6,000 patients with gout treated with either febuxostat or allopurinol.The primary outcome was a combination of heart-related death, non-deadly heart attack, non-deadly stroke, and a condition of inadequate blood supply to the heart requiring urgent surgery.The preliminary results show that overall, febuxostat did not increase the risk of these combined events compared to allopurinol.